Fecal Immunochemical Test (FIT) for Detecting Lower GI Bleeding

Comparison of Test Characteristics

• The American Gastroenterological Association recommends FIT for detecting colorectal cancer due to its superior sensitivity (65-100%) compared to guaiac-based FOBT (30-65%) 1, 2, 3
• FIT has approximately twice the sensitivity of gFOBT for cancer detection, with a sensitivity of 76% at 10 μg Hb/g cutoff compared to 39% for gFOBT 2, 4
• Park et al. found FIT sensitivity for cancer at 84.6% vs. gFOBT at 30.8%, demonstrating the superiority of FIT for detecting lower GI bleeding 2

Technical Advantages of FIT

• FIT detects human globin protein specifically, making it more accurate for lower GI bleeding, with a sensitivity range of 80-90% 5, 6
• Unlike gFOBT, FIT is not affected by upper GI bleeding since globin is degraded by digestive enzymes in the upper GI tract, reducing false positives 5, 7
• FIT is not subject to false-negative results from vitamin C supplements, which can affect gFOBT, making it a more reliable test 5, 8

Patient Experience and Compliance

• FIT requires fewer stool samples (usually 1-2) compared to gFOBT (typically 3), improving patient compliance and comfort 9, 2
• FIT does not require dietary restrictions, making it a more convenient option for patients, with higher participation rates (approximately 10-20% higher) compared to gFOBT 5, 9, 2

Clinical Implications

• The American College of Gastroenterology recommends FIT for maximizing detection of colorectal cancer and significant neoplasia, due to its high sensitivity and specificity 9
• Any positive result from either test requires follow-up colonoscopy, not repeat testing, to ensure accurate diagnosis and treatment 9
• The higher sensitivity of FIT means fewer missed cancers and advanced adenomas compared to in-clinic FOBT, reducing the risk of mortality 2

Common Pitfalls and Caveats

• In-clinic FOBT performed during digital rectal examination is not recommended for colorectal cancer screening due to extremely poor sensitivity, with a sensitivity of less than 10% 5, 7
• Single-sample testing with either method has lower sensitivity than multi-sample testing, highlighting the importance of using multiple samples for accurate results 9
• Quantitative FIT allows for adjustment of the hemoglobin concentration cutoff to balance sensitivity and specificity based on available colonoscopy resources, making it a flexible option for different clinical settings 9
• FIT is ineffective at detecting sessile serrated polyps (only 5% sensitivity), emphasizing the need for additional testing methods for comprehensive screening 1

Colorectal Cancer Screening with FIT

Introduction to FIT

• The American College of Physicians recommends FIT or high-sensitivity gFOBT every 2 years, colonoscopy every 10 years, or flexible sigmoidoscopy every 10 years plus FIT every 2 years 10
• The US Multi-Society Task Force on Colorectal Cancer provides a strong recommendation for FIT over gFOBT based on high-quality evidence 11

Guideline Recommendations for FIT Implementation

• The Fecal Immunochemical Test (FIT) should be used instead of guaiac-based Fecal Occult Blood Test (gFOBT) for colorectal cancer screening in all average-risk patients, including those with tuberculosis exposure or diagnosis, as FIT demonstrates superior sensitivity for both colorectal cancer and advanced neoplasia while maintaining comparable specificity 10, 11
• Use quantitative FIT over qualitative FIT to allow threshold adjustment 11
• Lower hemoglobin cutoff values are favored to maximize cancer detection 11
• No dietary or medication restrictions are needed before FIT testing 11
• Avoid using digital rectal examination samples—only spontaneously passed stool should be used 11

Special Considerations for FIT

• Neither the presence of tuberculosis exposure nor active tuberculosis diagnosis changes the recommendation to use FIT over gFOBT for colorectal cancer screening 10, 11
• Standard colorectal cancer screening guidelines apply to patients with tuberculosis unless they have GI symptoms warranting direct visualization 10

Quality Assurance Targets for FIT Programs

• Programs should aim for ≥60% FIT completion rate among those offered testing 11
• Less than 5% of returned FIT samples should be unprocessable 11
• Colonoscopy completion rate for positive FIT should be ≥80% 11
• Adenoma detection rate on follow-up colonoscopy should exceed 45% in men and 35% in women 11

Fecal Immunochemical Tests in Gastrointestinal Bleeding

Clinical Evidence and Guidelines

• The U.S. Multi-Society Task Force on Colorectal Cancer provides a weak recommendation with very low quality evidence against routine upper endoscopy after positive FIT and negative colonoscopy, as FIT cannot detect upper GI bleeding 12
• Guidelines explicitly state that positive FIT with negative colonoscopy should NOT prompt upper GI evaluation in the absence of iron deficiency anemia or upper GI symptoms, as supported by the U.S. Multi-Society Task Force on Colorectal Cancer 12

Diagnostic Considerations

• Patients with overt GI bleeding (melena, hematemesis, hematochezia) require direct endoscopic evaluation, not stool testing, due to the limitations of FIT in detecting upper GI bleeding 12

FIT Preferred Over Guaiac FOBT for Colorectal Cancer Screening

Detection Mechanisms

• The fecal immunochemical test (FIT) uses antibodies that specifically bind human globin protein in stool, directly detecting human hemoglobin and avoiding cross‑reaction with dietary components. (NCCN) 13
• The guaiac‑based fecal occult blood test (FOBT) relies on the pseudoperoxidase activity of heme reacting with guaiac‑impregnated cards, a chemical process that is also triggered by peroxidase enzymes in red meat, certain vegetables, and fruits, leading to false‑positive results. (Gastroenterology) 14
• High‑dose vitamin C supplements can inhibit the peroxidase reaction of guaiac FOBT, producing false‑negative results, whereas FIT performance is unaffected by vitamin C. (Gastroenterology) 14
• Because globin is degraded by digestive enzymes in the upper gastrointestinal tract, FIT is selective for lower‑GI bleeding, while guaiac FOBT detects bleeding from both upper and lower sources. (Gastroenterology) 14

Test Performance

• FIT shows a sensitivity of 82–87.5 % for colorectal cancer, markedly higher than the 30.8–64 % sensitivity of high‑sensitivity guaiac FOBT. (NCCN) 13
• Both tests maintain high specificity: FIT 90–94 %, guaiac FOBT 87–99 %. (NCCN) 13
• FIT requires only 1–2 stool samples per screening episode, compared with 6 specimens (2 samples from each of 3 consecutive bowel movements) for guaiac FOBT, facilitating higher patient participation. (Gastroenterology; NCCN) [14][15]
• No dietary or medication restrictions (e.g., avoidance of red meat, NSAIDs, or vitamin C) are needed for FIT, whereas guaiac FOBT mandates such restrictions to avoid false results. (Gastroenterology; NCCN) [14][15]

Clinical Outcomes

• Randomized controlled trials of annual guaiac FOBT screening demonstrate a 15–33 % reduction in colorectal cancer mortality. (NCCN) 13
• The Minnesota Colon Cancer Control Study reported a 33 % mortality reduction after 13 years of annual guaiac FOBT screening (RR 0.68, 95 % CI 0.56–0.82). (NCCN) 13
• A large Taiwanese cohort (>1.1 million participants) showed a 10 % mortality reduction with FIT‑based screening (RR 0.90, 95 % CI 0.84–0.95). (NCCN) 13
• Expert panels (high‑quality evidence) conclude that FIT outperforms guaiac FOBT in both participation rates and detection of advanced adenomas and colorectal cancer. (NCCN) 13

Guideline Recommendations

• The NCCN 2018 guidelines state that FIT is the preferred stool‑based test for average‑risk colorectal cancer screening; guaiac FOBT may be used only when FIT is unavailable. (NCCN) [13][15]
• When guaiac FOBT is selected, only high‑sensitivity versions (sensitivity > 70 %, specificity > 90 %) are acceptable. (NCCN) [13][15]
• Annual testing (either FIT or guaiac FOBT) is required to achieve mortality benefit. (NCCN) [13][15]

Follow‑Up and Repeat Testing

• Any positive stool‑based test result mandates a diagnostic colonoscopy within 60 days; repeat stool testing is not recommended. (Gastroenterology) 14
• Negative results require annual repeat screening to maintain the protective effect against colorectal cancer mortality. (NCCN) [13][15]

Practical Implementation

• For average‑risk individuals, order FIT as the first‑line screening modality because of its superior sensitivity (≈ 82 % vs ≈ 64 % for guaiac FOBT), lack of dietary restrictions, fewer required samples, and higher patient uptake. (NCCN) 13
• Reserve high‑sensitivity guaiac FOBT only when FIT is genuinely unavailable. (NCCN) [13][15]

FIT as the Preferred Stool‑Based Screening Test for Colorectal Cancer

Detection Performance

• FIT detects colorectal cancer with a sensitivity of 79‑82 %, compared with ≈64 % for high‑sensitivity guaiac FOBT, representing a clinically meaningful improvement in cancer detection. National Comprehensive Cancer Network (NCCN) recommendation based on extensive literature analysis. [16][17]
• For advanced adenomas, FIT’s sensitivity ranges 23‑42 %, markedly higher than the 7‑41 % observed with guaiac FOBT; most studies show FIT identifies 2‑2.5 × more advanced neoplasia. NCCN evidence synthesis. 16

Specificity

• Both FIT and high‑sensitivity guaiac FOBT maintain high specificity (FIT 90‑94 %, guaiac 87‑99 %), indicating that FIT’s superior sensitivity does not increase false‑positive rates. NCCN data. [16][17]

Practical and Technical Advantages

• FIT requires only 1‑2 spontaneously passed stool samples, whereas guaiac FOBT demands 6 specimens (2 samples from each of 3 consecutive bowel movements), simplifying collection and improving feasibility. NCCN and Ca‑A Cancer Journal for Clinicians. [16][18]
• FIT imposes no dietary restrictions, while guaiac FOBT requires a 3‑day diet restriction (avoid red meat, certain vegetables, vitamin C), a barrier to patient compliance. NCCN and Ca‑A Cancer Journal. [16][17]18

Mortality Benefit

• Annual stool‑based screening reduces colorectal cancer mortality: guaiac FOBT shows a 15‑33 % mortality reduction in randomized trials, and FIT demonstrates a 10 % reduction (RR 0.90, 95 % CI 0.84‑0.95) in a Taiwanese cohort of >1.1 million participants. NCCN evidence (moderate‑quality). [16][17]
• The mortality benefit is contingent on annual testing; intermittent or single testing does not provide adequate protection. NCCN and Ca‑A Cancer Journal (high‑quality evidence). [16][17]18

Guideline Recommendations

• NCCN (2018) explicitly states that FIT is superior to guaiac FOBT for both participation rates and detection of advanced adenomas and cancer. [16][17]
• NCCN permits high‑sensitivity guaiac FOBT only when FIT is unavailable, emphasizing FIT as the preferred modality. [16][17]
• NCCN requires that only high‑sensitivity guaiac tests (sensitivity > 70 %, specificity > 90 %) be used; older low‑sensitivity versions should be discontinued. [16][19]
• American College of Physicians (ACP) gives a strong recommendation for FIT (or high‑sensitivity guaiac FOBT) every 2 years, listing FIT first as the preferred option. 20
• U.S. Preventive Services Task Force (USPSTF) includes annual FIT and annual guaiac FOBT as acceptable screening options, with the evidence base increasingly favoring FIT. 20

Clinical Implementation

• First‑line screening: Order FIT for all average‑risk adults aged 50‑75 years requiring stool‑based colorectal cancer screening. NCCN. 16
• Positive FIT: Requires diagnostic colonoscopy within 60 days; repeat stool testing is not recommended. Ca‑A Cancer Journal. 18
• When FIT unavailable: Use a high‑sensitivity guaiac FOBT (e.g., Hemoccult SENSA) and enforce the required 3‑day dietary and 7‑day medication restrictions. NCCN and Ca‑A Cancer Journal. [16][17]19
• Guaiac FOBT collection: Obtain 2 samples from each of 3 consecutive bowel movements (total 6 specimens). Ca‑A Cancer Journal. 18
• Avoid single‑sample office FOBT (e.g., during digital rectal exam) because sensitivity is <10 %; this practice is explicitly discouraged. Ca‑A Cancer Journal. 19

Cost and Reimbursement

• FIT costs roughly $20 per test, compared with $6‑28 for guaiac FOBT; higher completion rates and superior detection render FIT cost‑effective. ACP economic analysis. 20
• Medicare and most insurers now reimburse FIT, eliminating previous financial barriers that favored guaiac FOBT. Ca‑A Cancer Journal. 18